Accelerated Approval: US FDA Explains ‘Reasonably Likely’ Determination Criteria

New draft guidance discusses the data necessary for deciding whether an effect on a surrogate or intermediate clinical endpoint is reasonably like to predict clinical benefit and can support accelerated approval.